A fluorogenic probe for granzyme B enables in-biopsy evaluation and screening of response to anticancer immunotherapies.

MLA

Scott, Jamie I., et al. “A Fluorogenic Probe for Granzyme B Enables In-Biopsy Evaluation and Screening of Response to Anticancer Immunotherapies.” Nature Communications, vol. 13, no. 1, May 2022, pp. 1–11. EBSCOhost, https://doi.org/10.1038/s41467-022-29691-w.

APA

Scott, J. I., Mendive-Tapia, L., Gordon, D., Barth, N. D., Thompson, E. J., Cheng, Z., Taggart, D., Kitamura, T., Bravo-Blas, A., Roberts, E. W., Juarez-Jimenez, J., Michel, J., Piet, B., de Vries, I. J., Verdoes, M., Dawson, J., Carragher, N. O., Connor, R. A. O., Akram, A. R., & Frame, M. (2022). A fluorogenic probe for granzyme B enables in-biopsy evaluation and screening of response to anticancer immunotherapies. Nature Communications, 13(1), 1–11. https://doi.org/10.1038/s41467-022-29691-w

Chicago

Scott, Jamie I., Lorena Mendive-Tapia, Doireann Gordon, Nicole D. Barth, Emily J. Thompson, Zhiming Cheng, David Taggart, et al. 2022. “A Fluorogenic Probe for Granzyme B Enables In-Biopsy Evaluation and Screening of Response to Anticancer Immunotherapies.” Nature Communications 13 (1): 1–11. doi:10.1038/s41467-022-29691-w.